FDA Clearance Tracker · P830061-S130
CAPSURE SENSE MRI SURESCAN LEAD MODEL 4574
Last checked: Nov 20, 2026Latest source record: Oct 25, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Oct 25, 2016
Approved
Time to decision
175 days
Received May 3, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P830061-S130
- Device name
- CAPSURE SENSE MRI SURESCAN LEAD MODEL 4574
- Applicant location
- Mounds View, MN
- Received
- May 3, 2016
- Decided
- Oct 25, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P830061
Device type
- Device type
- Drug eluting permanent right ventricular (RV) or right atrial (RA) pacemaker electrodes (NVN)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the Claria MRI/Claria MRI Quad CRT-D SureScan devices as well as the Amplia MRI/Amplia MRI Quad CRT-D SureScan and Compia MRI CRT-D SureScan device models with DF-1 connector compatibility.
Source documents
Other decisions for Medtronic Cardiac Rhythm Disease Management
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.